Cytomis600 mcg

Cytomis is a synthetic prostaglandin E1 analog whose approved and guideline-supported uses differ by clinical setting. All obstetric use of Cytomis must occur under direct medical/hospital supervision.

Established / FDA-approved use

• Prevention of NSAID-induced gastric ulcers: Cytomis is indicated to reduce the risk of gastric ulcers caused by long-term nonsteroidal anti-inflammatory drug (NSAID) therapy in patients at high risk of ulcer complications (e.g., elderly patients, those with a prior history of ulcer disease). It has not been shown to be effective in preventing duodenal ulcers due to NSAID use.

Guideline-supported obstetric uses (specialist/hospital supervision only)

• Labor induction and cervical ripening: Used to soften/dilate the cervix and stimulate uterine contractions when induction of labor is medically indicated.
• Prevention and treatment of postpartum hemorrhage (PPH): Recommended by WHO guidance, particularly where injectable uterotonics such as oxytocin are not available or feasible.
• Management of missed or incomplete miscarriage: Used to complete evacuation of retained products of conception under medical supervision.

Combination-therapy use

Cytomis is used together with mifepristone (a combination regimen) for medical termination of early pregnancy, in accordance with local law and clinical guidelines; used alone, Cytomis is less effective for this purpose than the combination regimen.

Off-label use

Cervical priming/ripening before gynecologic procedures such as hysteroscopy or intrauterine device insertion is a recognized off-label use of Cytomis in some clinical settings.

Each tablet of Misoprostol contains Misoprostol as the active pharmaceutical ingredient. Misoprostol is available in strengths including 25 mcg, 100 mcg, 200 mcg, and 600 mcg tablets, along with standard pharmaceutical excipients.

Cytomis is a synthetic analog of prostaglandin E1 (PGE1). It has two distinct pharmacologic actions that underlie its clinical uses: it inhibits gastric acid secretion and increases production of protective mucus and bicarbonate in the stomach lining (its antiulcer effect), and it stimulates uterine smooth muscle contraction while softening and dilating the cervix (its uterotonic/cervical-ripening effect). Because of this second action, Cytomis is used both as a gastroprotective agent in patients taking NSAIDs and, in carefully selected obstetric situations under medical supervision, as an agent to induce labor, manage miscarriage, or prevent/treat postpartum hemorrhage.

Prostaglandin E1 (PGE1) analog — antiulcer / gastroprotective agent and uterotonic agent.

Misoprostol and its active metabolite (misoprostol acid) bind to prostaglandin EP2/EP3 receptors.

• Gastroprotective action: Binding to EP3 receptors on gastric parietal cells inhibits basal and stimulated gastric acid secretion; Misoprostol also increases mucosal bicarbonate and mucus production, enhancing the stomach's natural defenses against NSAID-induced injury.
• Uterotonic action: Binding to EP2/EP3 receptors on uterine smooth muscle increases intracellular calcium, producing myometrial contraction; Misoprostol also promotes cervical ripening by altering the collagen structure of the cervix, allowing it to soften and dilate.

Misoprostol is rapidly absorbed after oral administration and de-esterified to its active free acid form; it is also absorbed vaginally, sublingually, and rectally, with different absorption/onset profiles by route. It is eliminated primarily via the kidneys, with a short elimination half-life.

Cytomis tablets may be taken orally (swallowed with water, with food to reduce diarrhea, for the ulcer-prevention indication), or, for specific obstetric indications under clinical supervision, administered vaginally, sublingually, or rectally as directed by the treating physician. Do not split, crush, or alter the route of administration except as specifically instructed, since absorption and effect differ by route.

Clinically significant interactions with Cytomis are limited:

• Magnesium-containing antacids: Co-administration can worsen diarrhea, a common side effect of Cytomis; magnesium-free antacids are preferred if antacid therapy is needed concurrently.
• Other uterotonic agents (e.g., oxytocin): When Cytomis is used for obstetric indications, concurrent use with other uterotonics can cause additive uterine stimulation and an increased risk of uterine hyperstimulation; such combinations are only used under close hospital monitoring per institutional protocol.
• NSAIDs: No adverse pharmacologic interaction occurs; in fact, Cytomis is specifically co-prescribed with NSAIDs to counteract their gastric toxicity, so this combination is intentional and expected.

The most common side effects of Cytomis involve the gastrointestinal tract and are generally dose-related:

• Diarrhea — the most frequent adverse effect; usually develops early in treatment and typically resolves within about a week, but occasionally requires dose reduction or discontinuation.
• Abdominal pain/cramping, nausea, dyspepsia, flatulence, and vomiting.
• Headache and dizziness have also been reported.

When Cytomis is used for obstetric indications, additional effects related to its uterotonic action can occur, including uterine hyperstimulation (excessively frequent or prolonged contractions) and, rarely but seriously, uterine rupture — the risk of which is notably higher in women with a prior cesarean section or other uterine surgery (see Precautions and Warnings).

Cytomis has fundamentally different implications in pregnancy depending on why it is being used, and this distinction is critical:

When used for NSAID-induced-ulcer prevention

Cytomis must NOT be used in pregnancy for this indication. It is an abortifacient and can cause miscarriage, premature labor, birth defects, or uterine rupture. Patients of reproductive potential must have a negative pregnancy test within 2 weeks before starting Cytomis for this indication and must use effective contraception throughout treatment; treatment should begin only on the second or third day of a normal menstrual period.

When used for obstetric indications (labor induction, cervical ripening, miscarriage management, or pregnancy termination in combination regimens)

Cytomis is deliberately administered during pregnancy for these purposes, but strictly under direct medical/hospital supervision, with appropriate monitoring, because of risks including uterine hyperstimulation and uterine rupture (particularly with a prior cesarean scar). Use only exactly as directed by the treating physician.

Lactation

Cytomis and its active acid metabolite are excreted in breast milk. Use during breastfeeding should occur only if clearly needed and under medical advice, since infant exposure and effects have not been fully characterized; a physician can advise on timing of breastfeeding relative to dosing if Cytomis is required.

Boxed warning – use in pregnancy for the ulcer-prevention indication

Cytomis must not be used for prevention of NSAID-induced ulcers in pregnant women: it can cause abortion, premature birth, birth defects, or uterine rupture in this context. Women of reproductive potential prescribed Cytomis for this indication must have a documented negative pregnancy test before starting and must use effective contraception throughout treatment. Do not share Cytomis with anyone else.

Uterine rupture risk in obstetric use

When Cytomis is used for labor induction or other obstetric indications, there is a risk of uterine hyperstimulation and uterine rupture, which is substantially higher in women with a prior cesarean delivery or other uterine surgery; such use requires hospital-level monitoring of fetal heart rate and uterine activity and should only be undertaken by an experienced clinician.

Diarrhea

Diarrhea associated with Cytomis can occasionally be severe; taking doses with food and avoiding magnesium-containing antacids can reduce this risk (see Interactions).

General

Cytomis should be used only under the direction of a physician; do not use for self-treatment of any condition, and do not use Cytomis obtained from unverified or informal sources.

Overdose of Cytomis may cause sedation, tremor, seizures, dyspnea, abdominal pain, diarrhea, fever, palpitations, hypotension, or bradycardia; in pregnant women, overdose can also provoke strong uterine contractions and uterine rupture. There is no specific antidote.

If overdose of Cytomis is suspected, seek immediate medical attention or contact emergency services / a poison control center right away. Do not attempt specific home treatment; management is supportive and should be provided by medical professionals.

Store at room temperature (below 30°C), away from light and moisture. Keep out of reach of children.

Renal impairment: No routine dose adjustment of Cytomis is required in patients with renal impairment, although clinical monitoring is advised.

Hepatic impairment: No specific dose adjustment has been established; use with routine clinical caution.

Elderly: No specific dose reduction is required based on age alone for the ulcer-prevention indication, but elderly patients are among those at highest risk for NSAID-induced ulcers and are a key target population for this use of Cytomis; monitor for diarrhea and dehydration.

Women of reproductive potential: Require a negative pregnancy test and effective contraception before starting Cytomis for the NSAID-ulcer-prevention indication (see Pregnancy and Lactation).

Pediatric patients: See Pediatric Uses.

For NSAID-induced ulcer prevention, Cytomis is generally continued for the entire course of NSAID therapy, as directed by the physician. For obstetric indications (labor induction, miscarriage management, PPH prevention/treatment), Cytomis is given as a short, defined course of doses under direct medical supervision, with duration determined by clinical response and monitoring rather than a fixed calendar period.

Prostaglandins (Prostaglandin E1 analogs)

Misoprostol binds prostaglandin EP2/EP3 receptors: on gastric parietal cells this suppresses acid secretion and boosts protective mucus/bicarbonate output (antiulcer effect); on uterine smooth muscle and cervical tissue it triggers contraction and promotes cervical softening/dilation (uterotonic/cervical-ripening effect).

X

Safety and efficacy of Cytomis for NSAID-induced ulcer prevention have not been established in children; pediatric NSAID-related gastroprotection is not a routine indication and pediatric use of Cytomis for this purpose is not recommended outside specialist guidance. Obstetric uses of Cytomis (e.g., pregnancy management) can apply to adolescent females who are pregnant, but only under direct specialist/hospital supervision, following the same precautions that apply to adult obstetric use.